Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020
-
Published:2024-04
Issue:
Volume:45
Page:101055
-
ISSN:2666-6065
-
Container-title:The Lancet Regional Health - Western Pacific
-
language:en
-
Short-container-title:The Lancet Regional Health - Western Pacific
Author:
Wei Yuxuan,
Zhang Yichen,
Xu Ziyue,
Wang Guoan,
Zhou Yue,
Li Huangqianyu,
Shi Luwen,
Naci Huseyin,
Wagner Anita K.,
Guan XiaodongORCID
Reference63 articles.
1. Cancer, Key facts;WHO,2020
2. Challenges and opportunities with oncology drug development in China;Bajaj;Clin Pharmacol Ther,2019
3. Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010-2019;Lythgoe;JAMA Netw Open,2022
4. Who goes first? Patterns of cancer drug approvals across four major regulatory authorities: EMA, FDA, Health Canada, and PMDA;Warner;JCO Oncol Pract,2023
5. Clinical benefit and expedited approval of cancer drugs in the United States, European union, Switzerland, Japan, Canada, and Australia;Hwang;JCO Oncol Pract,2022